Ernexa Therapeutics Inc. Notes Payable, Current
Ernexa Therapeutics Inc. (ERNA) had Notes Payable, Current of $2.25 million as of 2025-03-31, per its 10-Q filed 2025-05-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current
us-gaap:NotesPayableCurrent · last filed 2025-05-07
- 2025-03-31: Notes Payable, Current $2.25M.
- 2014-09-30: Notes Payable, Current $1.82M.
- 2014-06-30: Notes Payable, Current $1.45M.
- 2014-03-31: Notes Payable, Current $702.00K.
| Period end | Notes Payable, Current |
|---|---|
| 2025-03-31 | $2.25M 10-Q · filed 2025-05-07 |
| 2014-09-30 | $1.82M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $1.45M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $702.00K 10-Q · filed 2014-05-15 |
| 2013-12-31 | $631.00K 10-Q · filed 2014-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |